scholarly journals Iatrogenic Creutzfeldt-Jakob disease following human growth hormone therapy: case report

2002 ◽  
Vol 60 (2B) ◽  
pp. 458-461 ◽  
Author(s):  
Luís Otávio Sales Ferreira Caboclo ◽  
Nancy Huang ◽  
Guilherme Alves Lepski ◽  
José Antônio Livramento ◽  
Carlos Alberto Buchpiguel ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Case Report ◽  
Signal Intensity ◽  
Clinical Symptoms ◽  
Growth Hormone Therapy ◽  
Human Growth ◽  
Autopsy Material ◽  
Pituitary Glands ◽  
Jakob Disease ◽  
Mri Sequences

We report the case of a 41-year-old man with iatrogenic Creutzfeldt-Jakob disease (CJD) acquired after the use of growth hormone (GH) obtained from a number of pituitary glands sourced from autopsy material. The incubation period of the disease (from the midpoint of treatment to the onset of clinical symptoms) was rather long (28 years). Besides the remarkable cerebellar and mental signs, the patient exhibited sleep disturbance (excessive somnolence) from the onset of the symptoms, with striking alteration of the sleep architecture documented by polysomnography. 14-3-3 protein was detected in the CSF, and MRI revealed increased signal intensity bilaterally in the striatum, being most evident in diffusion-weighted (DW-MRI) sequences. This is the second case of iatrogenic CJD associated with the use of GH reported in Brazil.

scholarly journals Hyperthyroidism without Clinical Symptoms Found in Turner Syndrome During Human Growth Hormone Therapy

1993 ◽  
Vol 2 (Supple2) ◽  
pp. 107-110 ◽  
Author(s):  
Takashi Sakurai ◽  
Soichi Kodama ◽  
Sachiko Sakamoto ◽  
Hidehiro Yasujima ◽  
Hiroko Shimizu ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Turner Syndrome ◽  
Human Growth Hormone ◽  
Clinical Symptoms ◽  
Growth Hormone Therapy ◽  
Human Growth

scholarly journals Frequent Detection of Pituitary-Derived PrPres in Human Prion Diseases

2019 ◽  
Vol 78 (10) ◽  
pp. 922-929
Author(s):  
Hiroyuki Honda ◽  
Masaki Matsumoto ◽  
Masahiro Shijo ◽  
Hideomi Hamasaki ◽  
Shoko Sadashima ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Prion Protein ◽  
Prion Diseases ◽  
Human Growth ◽  
Pituitary Hormones ◽  
Cellular Prion Protein ◽  
Proteinase K ◽  
Molecular Weights ◽  
Pituitary Glands ◽  
Jakob Disease

Abstract Human prion diseases including sporadic Creutzfeldt-Jakob disease (sCJD), inherited prion diseases, and acquired human prion diseases are lethal neurodegenerative diseases. One of the major sources of iatrogenic Creutzfeldt-Jakob disease was human growth hormone (hGH-iCJD) derived from contaminated cadaveric pituitaries. The incidence of hGH-iCJD has decreased since changing from growth hormone extracted from human cadaveric pituitaries to recombinant pituitary hormones. However, extensive analysis on the localization and detecting of abnormal prion protein in the pituitary gland are limited. In this study, we examined 9 autopsied brains and pituitary glands from 6 patients with prion disease (3 Gerstmann-Sträussler-Scheinker disease, 2 sCJD, and 1 dura mater graft-associated CJD) and 3 individuals with nonprion diseases. Western blot analysis of pituitary samples demonstrated unique glycoforms of normal cellular prion protein with molecular weights of 30–40 kDa, which was higher than the typical 25–35 kDa prion protein in brains. Proteomic analysis also revealed prion protein approximately the molecular weight of 40 kDa in pituitary samples. Moreover, proteinase K-resistant Prion protein was frequently detected in pituitary samples of the prion diseases. Immunohistochemistry for Prion protein revealed mosaic cellular distribution preferentially in growth hormone- or prolactin-producing cells.

A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand

Neurology ◽  
1988 ◽  
Vol 38 (7) ◽  
pp. 1128-1128 ◽  
Author(s):  
M. Croxson ◽  
P. Brown ◽  
B. Synek ◽  
M. G. Harrington ◽  
R. Frith ◽  
...  
Keyword(s):  
Growth Hormone ◽  
New Zealand ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Human Growth ◽  
Jakob Disease

Creutzfeldt-Jakob disease after pituitary-derived human growth hormone therapy: Two cases with valine 129 homozygous genotype

Neurology ◽  
1994 ◽  
Vol 44 (1) ◽  
pp. 179-179 ◽  
Author(s):  
C. Masson ◽  
I. Delalande ◽  
J. P. Deslys ◽  
D. Henin ◽  
C. Fallet-Bianco ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Human Growth ◽  
Homozygous Genotype ◽  
Jakob Disease

Potential Epidemic of Creutzfeldt–Jakob Disease from Human Growth Hormone Therapy

1985 ◽  
Vol 313 (12) ◽  
pp. 728-731 ◽  
Author(s):  
Paul Brown ◽  
D. Carleton Gajdusek ◽  
C.J. Gibbs ◽  
David M. Asher
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Human Growth ◽  
Jakob Disease

Creutzfeldt-Jakob disease following pituitary-derived human growth hormone therapy: A new American case

Neurology ◽  
1988 ◽  
Vol 38 (7) ◽  
pp. 1131-1131 ◽  
Author(s):  
D. J. Marzewski ◽  
J. Towfighi ◽  
M. G. Harrington ◽  
C. R. Merril ◽  
P. Brown
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Human Growth ◽  
Jakob Disease ◽  
American Case

Using human growth hormone (somatropin)

1989 ◽  
Vol 27 (25) ◽  
pp. 97-98
Keyword(s):  
Growth Hormone ◽  
Young Adults ◽  
Short Stature ◽  
Human Growth Hormone ◽  
Gh Deficiency ◽  
Human Growth ◽  
Turner’S Syndrome ◽  
Human Pituitary ◽  
Pituitary Glands ◽  
Jakob Disease

Short stature was first treated in 1958 with growth hormone (GH) made from human pituitary glands.1 In 1985 biosynthetic GH was introduced after several young adults treated with GH in childhood had died from Creutzfeldt-Jakob disease.2 The first biosynthetic GH somatrem (Somatonorm - KabiVitrum) contains an additional methionyl residue and is licensed for treating short stature of Turner’s syndrome as well as GH deficiency. A preparation identical to human GH is now available (somatropin (rbe); Genotropin - KabiVitrum). Who should have it?

Sign in / Sign up

Export Citation Format

Share Document